Morgan Stanley analyst Michael Ulz raised the firm’s price target on Alnylam (ALNY) to $495 from $475 and keeps an Equal Weight rating on the shares. Amvuttra outperformed consensus again and TTR sales guidance was raised for the second time this year, though this was “largely expected,” the analyst tells investors in a post-Q3 note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Strong Sales Growth and Financial Performance Justify Buy Rating
- Alnylam reports Q3 EPS $1.84, consensus $1.75
- ALNY Upcoming Earnings Report: What to Expect?
- Alnylam Pharmaceuticals: Strong Market Performance and Promising Pipeline Drive Buy Rating
- Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment